This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 9 of 239 for:    macular degeneration | Recruiting, Not yet recruiting, Available Studies

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2017 by Bayer
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT02540954
First received: September 2, 2015
Last updated: September 8, 2017
Last verified: September 2017
September 2, 2015
September 8, 2017
September 29, 2015
January 12, 2021   (Final data collection date for primary outcome measure)
Change in Early Treatment Diabetic Retinopathy Study best corrected visual acuity (EDTRS BCVA) letter score for the study eye [ Time Frame: Week 52 ]
Same as current
Complete list of historical versions of study NCT02540954 on ClinicalTrials.gov Archive Site
  • Number of participants with adverse events as measure of safety and tolerability [ Time Frame: Week 52 and Week 76 ]
  • Proportion of subjects maintaining vision (i.e. loss of < 15 letters) in the study eye [ Time Frame: Week 52 ]
  • Proportion of subjects who gained from baseline ≥ 5 letters in the study eye [ Time Frame: Week 52 ]
  • Mean change from baseline in central retinal thickness (CRT) in the study eye [ Time Frame: Week 52 ]
  • Mean change from baseline in choroidal neovascularization (CNV) area in the study eye [ Time Frame: Week 52 ]
  • Proportion of subjects who lost ≥ 30 letters [ Time Frame: Week 52 ]
  • Mean change from baseline in total score for National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) [ Time Frame: Week 52 ]
Same as current
Not Provided
Not Provided
 
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of 2 mg Aflibercept Administered by Intravitreal Injections Using Two Different Treatment Regimens to Subjects With Neovascular Age-related Macular Degeneration (nAMD).
To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)
330 Patients who have completed at least one year of treatment with aflibercept will be randomized to two different aflibercept regimens and followed for 76 weeks.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Macular Degeneration
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
A dose of 2 mg aflibercept injected intravitreally
  • Experimental: Flexible dosing intervals
    Flexible dosing intervals: 2 mg aflibercept (Eylea) injected intravitreally with flexible injection intervals (more than 8 weeks)
    Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
  • Experimental: Fixed injection intervals
    2 mg aflibercept (Eylea) injected intravitreally with fixed injection intervals (8 weeks ±7 days)
    Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
330
January 12, 2021
January 12, 2021   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • The following criteria must have been met at the initial start of aflibercept treatment (i.e. start of aflibercept treatment at least 1 year before this study):

    • Subject had primary subfoveal choroidal neovascularization (CNV) lesions secondary to nAMD, including juxtafoveal lesions that affect the fovea, as evidenced by fluorescein angiography/photography (FA/FP) of the study eye within 3 weeks before the initiation of aflibercept treatment.
    • The area of CNV occupied at least 50% of the total lesion within 3 weeks before the initiation of aflibercept treatment.
    • Documented best-corrected visual acuity (BCVA) was 20/40 to 20/320 (letter score of 73 to 25) in the study eye at the initiation of treatment.
  • Men and women >= 51 years of age
  • The subject's history of aflibercept treatment meets ALL of the following:

    • Treatment in the study eye was initiated with three monthly (-1 week/+2 weeks) doses of 2 mg aflibercept and improvements of visual and anatomic outcomes were observed
    • Following the above initiation phase, the intervals between treatments were between 6 weeks and 12 weeks

Exclusion Criteria:

- Any prior or concomitant therapy with an investigational or approved agent to treat neovascular AMD in the study eye other than aflibercept.

  • Total lesion size > 12 disc areas (30.5 mm2, including blood, scars and neovascularization) as assessed by fluorescein angiography (FA) in the study eye
  • Subretinal hemorrhage that was:

    1. 50% or more of the total lesion area, or
    2. if the blood was under the fovea, and
    3. the blood under the fovea was 1 or more disc areas in size in the study eye.
  • Scar or fibrosis making up more than 50% of the total lesion in the study eye.
  • Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
  • Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.
  • Causes of CNV other than AMD in the study eye.
Sexes Eligible for Study: All
51 Years and older   (Adult, Senior)
No
Contact: Bayer Clinical Trials Contact +49 30 300139003 clinical-trials-contact@bayer.com
Austria,   Canada,   Czechia,   France,   Germany,   Hungary,   Italy,   Lithuania,   Poland,   Portugal,   Slovakia,   Spain,   Switzerland,   United Kingdom
Czech Republic
 
NCT02540954
16598
2013-000120-33 ( EudraCT Number )
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Not Provided
Bayer
Bayer
Regeneron Pharmaceuticals
Study Director: Bayer Study Director Bayer
Bayer
September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP